Agios Pharmaceuticals Enrolls First Patient In Phase 1 Study Of AG-120 In Advanced Solid Tumors With An IDH1 Mutation
3/24/2014 9:35:14 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein and a highly targeted, first-in-class therapeutic candidate.
Help employers find you! Check out all the jobs and post your resume.
comments powered by